Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An update from BioNano Genomics ( (BNGO) ) is now available.
On January 24, 2025, Bionano Genomics, Inc. executed a reverse stock split at a 1-for-60 ratio following approval in a special stockholder meeting. The split, effective from January 24, reduced the number of shares and adjusted exercise prices proportionately, with trading on a split-adjusted basis starting January 27. This move impacts all stockholders proportionately without altering percentage ownership.
More about BioNano Genomics
Bionano Genomics is a company providing genome analysis solutions, aiming to transform genome analysis through optical genome mapping technology. The company offers solutions for research and diagnostic services, including software for genome analysis and nucleic acid extraction using proprietary isotachophoresis technology.
YTD Price Performance: -52.55%
Average Trading Volume: 8,599,224
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $16.99M
Find detailed analytics on BNGO stock on TipRanks’ Stock Analysis page.
